Aptevo Therapeutics Inc. (APVO)

NCM – Цена в реальном времени. Валюта: USD

4.83

-0.01 (-0.31%)

При закрытии: May 12, 2026, 4:00 PM EDT

4.65

-0.18 (-3.73%)

До открытия: May 13, 2026, 4:00 AM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Aptevo Therapeutics Inc. (APVO)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Aptevo Therapeutics Inc. (APVO)

Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection

Aptevo Therapeutics (APVO) Upgraded to Buy: Here's Why

Aptevo Provides State of the Business Report and 2025 Financial Results

Aptevo to Participate in March 2026 Conferences

Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%

Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth

Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality

Видео

No Data

Пресс-релизы

Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection

Aptevo Provides State of the Business Report and 2025 Financial Results

Aptevo to Participate in March 2026 Conferences

Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%

Search stocks

Aptevo Therapeutics Inc. (APVO)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Aptevo Therapeutics Inc. (APVO)

Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection

Aptevo Therapeutics (APVO) Upgraded to Buy: Here's Why

Aptevo Provides State of the Business Report and 2025 Financial Results

Aptevo to Participate in March 2026 Conferences

Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%

Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth

Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality

Видео

No Data

Пресс-релизы

Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection

Aptevo Provides State of the Business Report and 2025 Financial Results

Aptevo to Participate in March 2026 Conferences

Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%